Herpes Simplex Virus Treatment Market Report, Share, Size & Trends 2022-27

Market Overview 2022-2027:

The latest research study “Herpes Simplex Virus Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” by IMARC Group, finds that the global herpes simplex virus treatment market reached a value of US$ 2.32 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 3.25 Billion by 2027 exhibiting a CAGR of 5.50% during 2022-2027.

Request a PDF Sample Copy for more detailed market insights: https://www.imarcgroup.com/herpes-simplex-virus-treatment-market/requestsample

Industry Definition and Application:

Herpes simplex virus (HSV), also commonly known as herpes, is a contagious infection that can spread through saliva, semen, and vaginal secretions and cause painful blisters or ulcers. The two most common types of HSV are HSV-1 and HSV-2, which can lead to genital infections and orofacial diseases such as cold sores. It is usually diagnosed through fluid sampling, physical examinations, and blood tests. Nowadays, individuals are widely adopting medications such as acyclovir, valacyclovir, Abreva, Blistex, docosanol, allantoin, and famciclovir, which can help relieve symptoms, reduce the frequency and severity of outbreaks, and prevent the transmission of the virus.

What are the major market drivers in the herpes simplex virus treatment market?

The market is primarily driven by the rising prevalence of HSV, which can also increase the risk of obtaining and transmitting human immunodeficiency virus (HIV) infection. In addition, it can lead to serious complications like encephalitis and keratitis in people with long-term or chronic illnesses such as diabetes and hypertension. Moreover, the rising outbreak of infectious diseases and increasing cases of hospital-acquired infections are augmenting the market growth. Additionally, the growing prevalence of low immunity disorders and the rising usage of unhygienic practices in various countries represent another major growth-inducing factor. Besides this, neonatal herpes can occur when an infant is exposed to HSV in the genital tract during delivery, which can cause lasting neurologic disability or death in infants.

Along with this, the increasing number of people undergoing organ transplantation is also escalating the need for HSV treatment, as bone marrow and solid-organ transplants can lead to the reactivation of HSV infection. Furthermore, the surging investments in research and development (R&D) activities for developing new antiviral medications and expanding the treatment options for orolabial and genital herpes, along with the increasing utilization of antiviral cream or ointment that can relieve burning, itching, or tingling sensations of HSV, are anticipated to propel the market growth in the coming years.

Click here to view detailed information with table of content: https://bit.ly/3vt6HPM

Report Segmentation:

The report has segmented the market on the basis of region, type, drug type, route of administration and distribution channel.

Breakup by Type:

• Herpes Simples Virus-1 Infection
• Herpes Simplex Virus-2 Infection
• Others

Breakup by Drug Type:

• Acyclovir
• Valacyclovir
• Famciclovir
• Others

Breakup by Route of Administration:

• Oral
• Injectable
• Topical

Breakup by Distribution Channel:

• Hospital Pharmacy
• Drug Stores
• Retail Stores
• Online Pharmacy

Breakup By Geography:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

List of Major Key Players:

The major players in the market are Agenus Inc., Apotex Inc., Avet Pharmaceuticals Inc., Carlsbad Tech, EPI Health LLC, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Merck & Co. Inc., Novartis AG, Sanofi S.A., Teva Pharmaceutical Industries Ltd. and Viatris Inc.

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact Us:

IMARC Services Private Limited.
30 N Gould St Ste R
Sheridan, WY 82801 USA – Wyoming
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800